According to a recent pharmacokinetic study, Levagen+ increased total absorption of palmitoylethanolamide (PEA), through use of LipiSperse, a dispersion technology.
According to a pharmacokinetic study published in the Journal of Nutraceuticals and Food Science1, Levagen+ (distributed by Gencor; Irvine, CA) increased total absorption of palmitoylethanolamide (PEA)- a naturally occurring endogenous fatty acid that supports biological functions related to aches, discomforts, and inflammation-through use of LipiSperse, a dispersion technology.
“To date, there has been limited data on the bioavailability of PEA in human plasma, and this study complements the existing literature showing PEA’s benefits,” said Mariko Hill, product development executive at Gencor. “The ability to increase PEA within blood plasma can, therefore, potentiate PEA’s positive benefits.”
In the parallel, double-blind absorption study, 28 healthy male and female participants were randomized into two groups: group one consumed 300 mg of Leagen+, Gencor’s PEA ingredient, with LipiSperse; group two consumed 300 mg of unprocessed PEA. Blood samples were taken at baseline, 30, 45, 60, 70, 90, 120, 280, and 240 minutes following ingestion. The results demonstrated that LipiSperse significantly increased plasma PEA concentration by 1.75 times compared to the standard PEA. The maximum concentration of PEA was observed at 45 minutes post ingestion.
1. Briskey D et al. “Increased absorption of Palmitoylethanolamide using a novel dispersion technology system (LipiSperse).” Journal of Nutraceuticals and Food Science, vol. 5, no.2 (2020): 3